Semaglutide
A GLP-1 receptor agonist with extensive human clinical trial data for metabolic endpoints.
What Semaglutide is
Semaglutide is a prescription GLP-1 analog with robust randomized clinical trial data. In a research-hub context it is the reference point for the metabolic peptide category, and the clearest example of a compound that belongs in a clinical, prescribed setting rather than the research-chemical market.
Mechanism (preclinical)
Agonizes the GLP-1 receptor, enhancing glucose-dependent insulin secretion and slowing gastric emptying, with central effects on satiety.
Primary research areas
Selected studies
Large RCT program (human)
2021Significant, sustained metabolic endpoint improvements vs. placebo.
Regulatory status
FDA-approved as a prescription drug. Obtain only through licensed clinical channels.
If you source Semaglutide for laboratory research
Buy only from a vendor that publishes a lot-matched COA from an independent laboratory. Check the lot number on the vial against the certificate. Read the HPLC result and the mass spectrometry result. Ask for the chromatogram.